BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 17, 2003
View Archived Issues
Tricyclic angiotensin AT2 agonists recently identified at Vicore
Read More
Miravant claims metalloporphyrin photosensitizers for cardiovascular PDT
Read More
Novel HIV protease inhibitors in early development at Merck
Read More
Novartis researchers describe novel proteasome inhibitors
Read More
Cytokine production inhibitors newly developed at Boehringer Ingelheim
Read More
Schering scientists present CDK and GSK-3 inhibitors for cancer and other uses
Read More
Wyeth develops novel modulators of 5-HT transporter
Read More
New antibacterial DNA gyrase inhibitors prepared and tested at Pfizer
Read More
Antiapoptotic fusion protein protects against ischemic brain injury
Read More
Blockade of myostatin leads to improvement in muscle function in dystrophic mice
Read More
AT-3639: new quinolone with antitumor activity generally comparable to etoposide
Read More
Velcade enters phase II trial in NSCLC
Read More
Ranbezolid development advances on two fronts
Read More
Potential of angiotensin receptor blocker in diabetic nephropathy
Read More
DN-101 evaluated in phase II trial in myelodysplastic syndromes
Read More
StressGen's HspE7 studied in NCI-sponsored trials for HPV-related diseases
Read More
Shire licenses Solaraze rights in Australia and certain Pacific Rim territories
Read More
Xenova buys out ImmuLogic's interests in TA-CD and TA-NIC programs
Read More
Enrollment complete in phase I/II trial of TheraCIM h-R3 in head and neck cancer
Read More
YM BioSciences' prostate cancer vaccine trial completes enrollment
Read More
Abbott to use Compugen technology to identify and prioritize new drug targets
Read More
Bolder receives grant to develop TPO proteins for thrombocytopenia
Read More
Antiarthritic effects demonstrated for a selective CXCR2 antagonist
Read More
Bioxel enters R&D collaboration for paclitaxel derivatives
Read More
Incara and Elan terminate option agreement for catalytic antioxidants
Read More
Neurion and Pfizer to model drug interactions with HERG ion channel
Read More
Structural GenomiX and Boehringer Ingelheim form collaboration
Read More
AstraZeneca's Oxis Turbuhaler completes mutual recognition procedure for COPD
Read More